US Market Report for Cerebrospinal Fluid Management 2017 - MedCore
NEW YORK, Dec. 16, 2016 /PRNewswire/ --
Description
For several years now there has been a shift from using fixed pressure shunts to pressure adjustable shunts. These shunts tend to have a lower revision rate and experience fewer complications, such as overdrainage, which makes them more popular among neurosurgeons and patients. However, fixed pressure shunts are still preferred by some neurosurgeons when treating pediatric patients. The fixed pressure devices are smaller and easier to use in these cases. The majority of shunts sold are pressure adjustable even though the ASP is also considerably higher for these devices. The move towards pressure adjustable shunts will continue over the forecast period as they cannibalize market share from fixed pressure shunts, increasing the market value. The ASP will continue to increase for pressure adjustable shunts as end-users switch to premium-priced products that have additional features such as antimicrobial coating. The ASP will remain relatively stable for fixed pressure shunts, with a slight appreciation due to the incorporation of new features.
Abstract
Devices in the cerebrospinal fluid (CSF) management market are mainly used for the treatment of hydrocephalus. Hydrocephalus, or "water on the brain," refers to an abnormal buildup of CSF in the brain's ventricles. Under normal biological conditions, equilibrium between the production, circulation and absorption of CSF is maintained in the ventricular cavities of the brain as CSF is continually drained away into the circulatory system. Hydrocephalus can result when absorption of fluid into the bloodstream is blocked which leads to an accumulation of CSF. This condition can result in increased intracranial pressure inside of the skull and can lead to tunnel vision, mental disability, progressive enlargement of the head and even death. Symptoms due to the increased intracranial pressure include headaches, nausea, vomiting, papilledema, coma or sleepiness. Further elevation of intracranial pressure can result in uncal and/or cerebellar herniation.
Scope:2013-2023
Companies
Medtronic
Boston Scientific
St. Jude Medical
Cyberonics
Codman & Shurtleff
Stryker
Integra LifeSciences
InoMed
Mizuho America
RauMedic
Read the full report: http://www.reportlinker.com/p04353027-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article